Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Pembrolizumab + SGN-B6A
Indication/Tumor Type head and neck squamous cell carcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive head and neck squamous cell carcinoma predicted - sensitive Pembrolizumab + SGN-B6A Phase I Actionable In a Phase I trial (SGNB6A-001), SGN-B6A and Keytruda (pembrolizumab) combination treatment demonstrated safety and activity in patients with CD274 (PD-L1)-positive (CPS >=1) head and neck squamous cell carcinoma, resulting in a confirmed overall response rate of 37.5% (3/8) with 2 confirmed complete response and 1 confirmed partial response (J Clin Oncol 2025 43: 16_suppl, 3122; NCT04389632). detail...
PubMed Id Reference Title Details
Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001). Full reference...